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Abstract: 
Tuberculosis (TB) is an intractable chronic infection.  Disease treatment 
with anti-TB drugs remains challenging due to drug-induced 
hepatotoxicity.  The toxicity of the anti-TB drugs rifampicin (RIF), isoniazid 
(INH), and pyrazinamide (PZA) either alone or in combination was 
investigated in HepG2 cells.  Assays of intracellular ATP levels at 4, 24, and 
48 hour post-exposure to gradient concentrations of RIF, INH, and PZA 
were conducted.  Drug-induced effects on mitochondrial membrane 
potential (MMP), mitochondrial complex I & complex III activity, NAD+ 
levels, and cellular lactate production were assessed.  Decreased ATP levels 
were dose-dependent and correlated with drug exposure 
duration.  Approximate 24 hour IC50s were 0.5 mM, 70 mM, and 84 mM 
for RIF, INH, and PZA, respectively.   Twenty-four hours post-drug 
treatment, reductions of MMP (p = 0.0005), mitochondrial complex I & III 
activities (p = 0.0001 & p = 0.0003, respectively), NAD+ levels (p = 
0.0057), and increased lactate production (p < 0.0001) were 
observed.  Drug combinations used to mimic cumulative drug treatments 
induced a synergistic inhibition of mitochondrial complex I activity.  An 
assessment of cellular ultrastructure using transmission electron 
microscopy indicated drug-induced mitophagy.  Collectively, our study 
suggests that hepatotoxicity of commonly employed anti-TB drugs is 
mediated by their curtailment of mitochondrial function. 
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Abstract  
Tuberculosis (TB) is an intractable chronic infection.  Disease treatment with anti-TB drugs 
remains challenging due to drug-induced hepatotoxicity.  The toxicity of the anti-TB drugs 
rifampicin (RIF), isoniazid (INH), and pyrazinamide (PZA) either alone or in combination was 
investigated in HepG2 cells.  Assays of intracellular ATP l vels at 4, 24, and 48 hour post-
exposure to gradient concentrations of RIF, INH, and PZA were conducted.  Drug-induced 
effects on mitochondrial membrane potential (MMP), mitochondrial complex I & complex III 
activity, NAD+ levels, and cellular lactate production were assessed.  Decreased ATP levels were 
dose-dependent and correlated with drug exposure duration.  Approximate 24 hour IC50s were 
0.5 mM, 70 mM, and 84 mM for RIF, INH, and PZA, respectively.   Twenty-four hours post-
drug treatment, reductions of MMP (p = 0.0005), mitochondrial complex I & III activities (p = 
0.0001 & p = 0.0003, respectively), NAD+ levels (p = 0.0057), and increased lactate production 
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(p < 0.0001) were observed.  Drug combinations used to mimic cumulative drug treatments 
induced a synergistic inhibition of mitochondrial complex I activity.  An assessment of cellular 
ultrastructure using transmission electron microscopy indicated drug-induced mitophagy.  
Collectively, our study suggests that hepatotoxicity of commonly employed anti-TB drugs is 
mediated by their curtailment of mitochondrial function. 
 
Keywords 
Anti-TB drugs, drug-induced hepatotoxicity, mitochondrial complex I & complex III activity, 
mitochondrial membrane potential, mitophagy. 
Introduction 
Tuberculosis (TB) is an airborne infectious disease.  Treatment of TB remains one of the major 
public health challenges in the world today. In 2013, 9 million people developed TB, and 1.5 
million died from the disease.1 Rifampicin (RIF), isoniazid (INH), and pyrazinamide (PZA) are 
basic (first-line) anti-TB drugs.2 The treatment regimen currently used in some developing 
countries is a fixed-dose, single-tablet combination of four drugs: RIF, INH, PZA, and 
ethambutol (EMB) for 2 months, followed by 4 months of INH-RIF and/or EMB.  The multi-
drug combination is employed at the intensive phase of treatment in an attempt to reduce primary 
INH-RIF combination drug resistance.2 Additionally, the use of fixed dose combination tablets 
can improve patient adherence to treatment.3 However, adverse drug reactions during TB 
treatment persist for which there are risk factors that include gender, age, malnutrition, co-
infection with HIV, and liver functionality.4 
Specifically, anti-TB drug-induced hepatotoxicity during standard multidrug TB 
treatment has been reported, with incidence influenced by a similar set of risk factors. 4-7 
However, patients with anti-TB drug-induced elevation of liver transaminase levels may still be 
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asymptomatic.6,8 Of the anti-TB drugs prescribed: RIF, INH, and PZA are potentially 
hepatotoxic 9-14, whereas no hepatotoxicity has been described for ethambutol.2  
Although the induction of anti-TB drug-induced hepatotoxicity has been documented, the 
mechanism by which individual or combinatorial anti-TB drugs influence cell viability and 
mitochondrial bioenergetics has not been extensively studied.  Herein we have investigated the 
potential hepatotoxicity of commonly employed anti-TB drugs, and provide a mechanistic 
insight into individual drug or dual-drug combination contributions to drug-induced 
hepatotoxicity. 
Materials and Methods 
Chemical agents  
The antibiotic, Rifampicin (5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-
heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-
(epoxypentadeca[1,11,13]trienimino)-naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate), 
(C43H58N4O12; MW = 822.94 g/mol); antibacterial agents Isoniazid (pyridine-4-carbohydrazide) 
(C6H7N3O), MW 137.13 g/mol), and Pyrazinamide (pyrazine-2-carboxamide) (C5H5N3O, MW = 
123.11 g/mol) were all purchased from Sigma (St Louis, MO, USA).  For assays, drugs were 
dissolved in DMSO, and diluted into serum-free media when applied to cells.  Additions of 
vehicle (DMSO) only at identical dilutions to that of assay samples were used to generate control 
readings for all assays. All other chemicals and media components were also purchased from 
Sigma unless specified.    
Cell culture 
Human hepatocellular carcinoma cells (HepG2 cells) were grown in serum-free PC-1 medium 
(Cambrex) supplemented with 2 mM L-glutamine. Cells were incubated at 37 ºC in a humidified 
atmosphere with 5% CO2.  
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Intracellular ATP content determination  
Cells were seeded in 96-well plates at 1 x 104 cells/well. At confluence cells were treated with 
the anti-TB drugs at concentrations of 0.1, 1, 10, and 100 mM for INH or PZA, and 
concentrations of 1 µM, 10 µM, 0.1 mM, and 1 mM for RIF.  After 4, 24, and 48 hrs cells were 
harvested and intracellular ATP content determined according to the manufacturer’s protocol 
(Abcam, Cambridge, MA, USA). Briefly, 50 µl of the supplied cell lysis buffer was added to 
each well, and the plates were shaken for 5 minutes. Then 50 µl of the reconstituted substrate (D-
Luciferin) was added to each well. Plates were placed on an orbital shaker for 5 minutes and then 
kept in the dark for further 10 minutes. The microplate scintillation counter ‘TopCount’ (Perkin 
Elmer) was used to determine intracellular ATP levels. Basal values in medium were subtracted 
from each test value.  Intracellular ATP levels are represented as a percentage of vehicle 
controls.  Experiments were conducted in triplicates. 
Mitochondrial membrane potential (MMP) measurements 
HepG2 cells were seeded in 24 well plates at a density of 3 x 104 cells/well. At confluence cells 
were treated for 24 hours with the anti-TB drugs: RIF at 0.1 and 0.5 mM, INH at 10 and 70 mM, 
and PZA at 10 and 84 mM. The media was removed and the Mitotracker green assay performed 
according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). Mitotracker green 
staining solution was added and the plates incubated at 37 ºC for 30 minutes.  A weak 
hydrophobic acid, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), a 
protonophoric uncoupler of oxidative phosphorylation in mitochondria, was used as a positive 
control. After staining, fluorescence was read in fresh phosphate buffer saline (PBS) using a 
Dyne MRX microplate reader (Dyne technologies, VA, USA) using excitation/emission filters of 
490⁄451nm, respectively. 
Mitochondrial complex I & III activity assays  
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HepG2 cells were treated with RIF (0.1 and 0.5 mM), INH (10 and 70 mM), and PZA (10 and 84 
mM) for 24 hrs. Complex I and complex III activities were assayed.  For Complex I assays, a 
mitochondrial-enriched fraction was used, prepared according to the procedure of Spinazzi et 
al.15 in 10 mM ice-cold hypotonic Tris buffer (pH 7.6) containing 1.5 M sucrose.  2,6-
Dichloroindophenol (DCIP) sodium salt hydrate was used as the terminal electron acceptor.16  
Complex I buffer was composed of 25 mM K-phosphate pH 7.6, 0.12 mM DCIP, 70 µM 
decylubiquinone (DUB), and 1µM antimycin A. Fatty acid free BSA (35 mg) was added, and the 
reaction started by the addition of NADH (10 mM). Complex I activity was quantified by 
monitoring the reduction of DCIP at 620 nm. 
Complex III activity was measured according to the procedure of Spinazzi et al.15; measuring the 
ability of the cell lysate to reduce Cytochrome C monitored by a change in absorbance at 550 
nm. Specific complex III activity was calculated as the difference between activities measured in 
the absence and presence of 2 mM antimycin A.  
To study the effect of combinations of anti-TB drugs upon complex I activity, cells were 
pretreated with RIF, INH, and PZA at concentrations of 30 µM, 3 mM, and 3 mM, respectively 
for 48 hours before initiation of the activity assays.  At these drug concentrations ATP levels 
were not significantly reduced.  After removal of media, cells were washed with PBS and then 
exposed to RIF (0.1 or 0.5 mM), INH (10 or 70 mM), or PZA (10 or 84 mM).  After 24 hours, 
Complex I and III activity measurements were taken. 
Cellular NAD+/NADH measurements 
Cellular NAD+/NADH levels were determined using a commercial kit (product 600480, Cayman 
Chemical, USA), according to the manufacturer’s protocol.  HepG2 cells were seeded at 0.1 x 
104 cells per well in 96 well plates, and grown until confluent.  Once confluent, culture media 
was removed and cells treated with the anti-TB drugs at their IC50 concentrations. After 24 hours, 
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120 µl of assay buffer was added and then the plates centrifuged at 500 x g for 5 minutes.  Assay 
buffer was removed and then 110 µl of permeabilisation buffer added to each well. Plates were 
shook for 30 minutes at room temperature and then centrifuged at 1000 x g for 5 minutes at 4 ºC.  
One hundred µl of the supernatant was removed to a fresh plate, followed by 100 µl of reaction 
buffer.  Plates were shook for 90 minutes before absorbance readings taken at 450 nm. Reagent 
only blanks were subtracted from the absorbance of all wells. The absorbance measurements of 
drug-treated samples were represented relative to vehicle controls.  Experiments were performed 
in triplicates. 
Lactate production assays 
HepG2 cells were seeded in 24-well plates at 5 × 104 cells/well. At confluence cells were treated 
for 24 hours with RIF (0.01 and 0.5 mM), INH (10 and 70 mM), and PZA (10 and 84 mM). 
After trypsinization, cells were counted, and cell supernatant media removed and assayed 
immediately for lactate levels using a lactate assay kit (Biovision, USA) according to the 
manufacturer’s protocol. Lactate production was normalized to cell number and expressed as a 
percentage of lactate production from control cells.  Experimental data points were performed in 
triplicates. 
Transmission Electron Microscopy 
HepG2 cells were grown to near confluence in EMEM with 2 mM Glutamine, 1 % non-essential 
amino acids, and 10 % Foetal Bovine Serum in 175 cm2 flasks.  Media was removed and replaced 
with media containing low serum (2 %) and cells grown for 24 hours.  Cells were then incubated 
with media containing the anti-TB drugs RIF, INH, or PZA at concentrations of 0.5, 70, & 84 
mM, respectively.  After 24 hours of drug treatment, media was removed and cells washed with 
media containing fixative (3 % glutaraldehyde in 0.1 M cacodylate buffer). The 1:1 (v/v) 
media:fixative solution was replaced with fixative alone, and cells fixed in the cell incubator for 
Page 7 of 28
http://mc.manuscriptcentral.com/het
Human & Experimental Toxicology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
1 hour at 37 ºC.  Flasks were removed and cells scraped into the fixative.  Cells were collected 
by centrifugation at 1500 rpm for 5 minutes at 4 ºC, and then further fixed for 1 hour at 4 ºC.  
Cells were washed in 0.1 M cacodylate buffer, transferred to flat-bed embedding capsules, and 
then incubated for 1 hour with 1 % osmium tetroxide in 0.1 M cacodylate buffer.   Cells were 
washed with water and then dehydrated with a graded ethanol series of 50, 70, 90, & 100 % 
ethanol, and a transitional solution, 100 % propylene oxide (propox).  Cells were infiltrated with 
an epoxy resin:propox mix (1:1) overnight, and then infiltrated with epoxy resin 3 times for 2 
hours each the following day.  Samples were then embedded and polymerized in an oven at 60 
ºC for 48 hours.  Ultra-thins of the cells (80 nm) were sectioned with a diamond knife on a Leica 
EM UC6 ultra microtome, collected, and placed on 200 mesh copper grids.  Sections were 
analysed using a Tecnai G2 BioTWIN transmission electron microscope (TEM) (FEI company, 
Eindhoven, The Netherlands), which was run at an accelerated voltage of 100 kV.  For each cell 
treatment up to 19 fields of view were analysed, with random unbiased selection. Images were 
captured using a MegaView SIS camera, with representative images included in Figures.   
Statistical Analysis 
All statistical procedures were performed using PRISM 5 (GraphPad Software Inc., San Diego, 
CA). For the 50 % inhibitory concentration (IC50), curve fitting was performed using single use 
Log (antagonist) versus response (variable slopes). A one way analysis of variance (ANOVA) 
test was performed with Dunnett’s multiple comparisons post-test. Unpaired Student’s t-tests 
were performed for two group comparisons.  Data points or histograms in Figures represent 
means ± SEMs, with differences compared to control values set at 100 % of activity. Statistical 
significance was defined as p < 0.05. For Figures, significance is represented as *** for p < 
0.001,** for p < 0.01, and * for p < 0.05. 
Results  
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Hepatotoxicity of anti-TB drugs 
To assess the influence of the anti-TB drugs RIF, INH, and PZA on cellular ATP levels, HepG2 
cells were incubated with each drug over a broad concentration range for up to 48 hours (Figure 
1).  Collectively, all drugs reduced ATP levels in a concentration- and exposure duration- 
dependent manner; albeit with similar drug profiles for 24 & 48 hour incubations (Figure 1). RIF 
was the most potent drug as it significantly reduced ATP levels (p = 0.0021) 4 hours post-
treatment at a concentration of 0.1 mM.   A summary of the approximate IC50 values for each 
drug are listed in Table 1. 
Drug-induced uncoupling of mitochondrial bioenergetics 
A mitotracker green assay was performed to quantify the effect of the tested anti-TB drugs on 
mitochondrial membrane potential (MMP).  Drugs were applied at their ~IC50 values as 
determined by the ATP assay and also at lower concentrations of 0.1 mM, 10 mM, & 10 mM for 
RIF, INH, & PZA, respectively.   All drugs at their IC50 concentrations significantly decreased 
MMP by ~40 % 24 hours post-exposure (p = 0.0005). At the lower tested concentrations all 
drugs reduced MMP by ~12-15 % but this did not reach significance (Figure 2).  
These drug concentrations were then assessed for inhibitory activity toward 
mitochondrial complex-I (MC-1) activity.  At their IC50 concentrations RIF, INH, and PZA 
significantly inhibited MC-I activity (p = 0.0001) by approximately 40, 43, and 33%, 
respectively (Figure 3, upper panel).  Additionally at a concentration of 0.1 mM RIF also 
significantly reduced MC-I activity by ~20% (Figure 3, upper panel).   Mitochondrial complex-
III (MC-III) activity was less sensitive to drug inhibition, and was inhibited by RIF and INH only 
at their ~IC50 concentrations (~30 % inhibition, p = 0.0003), whereas PZA at an IC50 
concentration did not significantly reduce MC-III activity (Figure 3, lower panel).  
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To further verify the uncoupling of mitochondrial activity we also quantified cellular 
NAD+ levels.  Incubation of cells at IC50 concentrations for RIF & INH significantly reduced 
cellular NAD+ levels by 41 % and 39 %, respectively (p = 0.0057).  A 21 % reduction of NAD+ 
levels at the IC50 concentration for PZA was observed, but this did not reach significance (Figure 
4). 
 As combinations of these anti-TB drugs are medically prescribed for patients suffering 
from TB, we also investigated the effects of drug combinations on MC-I activity. Cells were pre-
incubated with anti-TB drugs at concentrations of 30 µM, 3 mM, and 3 mM for RIF, INH, and 
PZA, respectively, for 48 hours.  At these drug concentrations ATP levels were not significantly 
reduced (Figure 1).  Cells were subsequently treated with RIF at 0.5 mM (24 hour IC50 
concentration) and MC-I activity quantified (Figure 5A).  At this RIF concentration, MC-I 
activity was significantly reduced to ~60 % of control values, similar to a single drug incubation 
(as observed in Figure 2).  Incubations of cells with RIF at 0.5 mM and addition of either INH (3 
mM) or PZA (3 mM) reduced MC-I activity a further 1-10 %, but this was not significant (Figure 
5A).  By contrast, incubation of cells with RIF at a lower concentration of 0.1 mM reduced MC-I 
activity to ~82 % of controls (similar to Figure 2), but the combination of RIF (0.1 mM) with 
INH (3 mM) significantly reduced MC-I activity by a furth r 21 % (p =0.0417) (Figure 5B).  
Cells incubated with RIF (0.1 mM) and PZA (3 mM) evoked a 2 % non-significant reduction of 
MC-I activity. 
Cell incubation with INH at 70 mM significantly reduced MC-I activity to ~56 % of 
controls (similar to Figure 2), and this was also further reduced by 10 & 3 % with additions of 
either RIF (3 µM) or PZA (3 mM), respectively, but these reductions were not significant (Figure 
5C).  Incubation of cells with INH at 10 mM produced an ~15 % fall of MC-I activity (similar to 
Figure 2), but notably a further significant ~16% reduction of MC-I activity (p =0.0466) was 
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observed with the INH and RIF (3 µM) drug combination (Figure 5D).  Incubation with INH (10 
mM) and PZA (3 mM) produced a 4 % non-significant further reduction of MC-I activity (Figure 
5D). 
Incubation of cells with 84 mM PZA produced a 36 % reduction of MC-I activity, in 
keeping with Figure 2, and although this was further reduced by 4 and 14 % with additions of 
RIF (3 µM) and INH (3 mM), respectively, these changes were not significant (Figure 5E).  
Incubation with 10 mM PZA reduced MC-I activity by 10 % (as seen in Figure 2), and this was 
further reduced by co-incubation with 3 µM RIF (12 %, non-significant), and INH at 3 mM (~21 
% significant, p = 0.0078) (Figure 5F). 
To study the bioenergetic shift of HepG2 cells to anaerobic metabolism due to the 
influence of anti-TB drugs, cellular production of lactate was measured. RIF, INH, and PZA at 
their IC50 concentrations all significantly increased cellular lactate production (p <0.0001) by 
approximately 41, 37, and 16 %, respectively (Figure 6).  However, lower drug concentrations 
(0.1, 10, and 10 mM for RIF, INH, and PZA, respectively) did not induce a significant change of 
lactate levels (Figure 6).  
Drug-induced cellular damage 
To assess cellular and mitochondrial damage as a consequence of anti-TB drug treatment, cells 
were incubated with anti-TB drugs for 24 hours at their IC50 concentrations and then fixed for 
TEM.  Control cells were relatively rich in rod-shaped mitochondria, with well-defined cristae, 
and displayed relatively few vacuoles (Figure 7A).  By contrast, cells treated with RIF displayed 
spherical mitochondria, abundant vacuoles indicative of removal of damaged mitochondria by 
mitophagy, and vacuoles thought to contain degrading mitochondria (mitophagolysosomes)  
(Figure 7B).  For cells treated with INH or PZA, rod-shaped mitochondria similar to control cells 
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were observed, but also spherical mitochondria and presumed mitophagic vacuoles were present 
(Figures 7C &7D). 
Discussion 
Anti-TB drug-induced liver insult is a leading cause of drug-induced acute liver injury and 
failure in the developing world.17 However, the correlation between serum anti-TB drugs levels 
and drug-induced hepatotoxicity remains unclear.7 Collectively, there are toxicity concerns 
regarding the use of anti-TB drugs as either dual-drug combinations or as a four drug fixed-dose 
combination, with subjects ranging from asymptomatic elevation of liver enzymes to displaying 
severe hepatitis.4-14,18  
           We show here that the anti-TB drugs RIF, INH, & PZA significantly reduce ATP levels in 
HepG2 cells in a concentration- and exposure duration- dependent manner.  The antibiotic RIF 
with the lowest estimated IC50 was the most potent inhibitor. At these IC50 concentrations a 
concurrent and significant decrease of MMP, inhibition of MC-I & MC-III activities, decrease of 
NAD+ levels, and increased cellular lactate production were also observed.  To establish a drug 
dose and effect relationship, drug concentrations below IC50 values were also examined.  At 
these lower drug concentrations reduced MMP, MC-I, & MC-III activities were still evident, but 
they did not reach significance except for RIF inhibition of MC-I activity at 0.1 mM. 
Mitochondrial protein Complexes I & III are components of the electron transport chain 
(ETC) that is crucial for cellular respiration and the generation of ATP.  MC-I (NADH: 
ubiquinone oxidoreductase) oxidizes NADH produced predominantly from the tricarboxylic acid 
(TCA) cycle, but also from β-oxidation of fatty acids.  Two electrons are produced from NADH 
oxidation, and these are used to reduce ubiquinone to ubiquinol in the inner mitochondrial 
membrane, and initiate the supply of electrons to be passed through the ETC to reduce oxygen to 
water.  This MC-I redox reaction also drives proton transport across the inner mitochondrial 
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membrane.  Similarly, electron transport is coupled to proton translocation in MC-III and IV, and 
this proton motive force supports ATP synthesis in complex V.19,20 Hence drug-induced 
inhibition or dysfunction of MC-I, and/or MC-III will limit the transfer of electrons along the 
ETC, driving the loss of the MMP, reduced NADH oxidation (NAD+ production), and ultimately 
a breakdown of cellular ATP production (Figures 1-4), and increased anaerobic metabolism and 
lactate production (Figure 6).  
In support of our results, drugs or oxidants that induce mitochondrial damage can 
provoke a progressive loss of cellular energy (ATP) resource, mitochondria degeneration, and 
ultimately cell death.21-24 Indeed mitochondrial dysfunction is suggested to play a crucial role in 
the etiology of drug-induced toxicities. Medication-induced mitochondrial dysfunction may arise 
through several mechanisms including direct inhibition of mitochondrial DNA transcription of 
electron transport chain (ETC) complexes, and the inhibition of the enzymes required for 
glycolysis and β-oxidation.25-27  In addition, inhibition of mitochondrial complexes, particularly 
MC-I, can increase the production of reactive oxygen species (ROS).28 ROS can damage cellular 
components including lipids, proteins, and DNA. Hence once mitochondria are damaged there 
will be a disruption of cellular bioenergetics.27   In support of this work, agents with anti-
oxidative activity have been shown to exhibit hepato-protective effects, able to prevent anti-TB 
drug-induced hepatotoxicity.29,30 
          Our strategy of drug pre-treatment followed by subsequent cellular dosing provides an in 
vitro model to mimic cumulative drug treatment in vivo.30  Our study has highlighted that a 
combination of anti-TB drugs may significantly increase their adverse effect on MC-I activity; 
presumably leading to exacerbated drug toxicity.  A further reduction of MC-I activity was 
registered even with drugs employed at their IC50 concentrations (Figures 5A,C,E), but 
moreover, with drug concentrations that produced a 10-20 % reduction of MC-I activity, a 
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further dual-drug treatment of RIF + INH, or PZA + INH combinations were able to further 
significantly reduce MC-I activity (Figures 5B,D,F).  The concentration of drugs used for pre-
treatments reflected relatively high therapeutic dose levels, but for which no detectable depletion 
of ATP levels were evidenced.  For RIF, a literature review has suggested that the current 
recommended 600 mg daily could be further increased to be more clinically efficacious without 
induction of toxicity.31 Ultimately, this synergistic effect of inhibiting MC-I activity at high 
therapeutic dose levels could be a contributing factor to patient hepatotoxicity experienced by 
dual- or multi- drug combinations.  
 Damaged or excessive mitochondria are targeted for degradation and elimination by an 
autophagosome pathway. Autophagosomes fuse with lysosomes to form mitophagolysosomes 
(autolysosomes) in which the enveloped contents are degraded.  This process of mitophagy can 
be cytoprotective and triggered in response to mitochondrial damaging agents that disrupt the 
MMP, generate ROS, and deplete cellular ATP levels.32-34  With TEM we were able to detect the 
presence of spherical mitochondria, extensive vacuolization, and the presence of vacuoles 
thought to contain degrading mitochondria (mitophagolysosomes) in response to drug 
incubations (Figure 7).  These mitochondrial changes are similar to those observed in liver cells 
as a response to acute toxicological insult from ethanol34. Changes to mitochondrial morphology 
and evidence of mitophagy was most apparent for RIF-treated cells, consistent with this drug’s 
relatively higher mitochondrial toxicity as determined by a reduction of MMP, mitochondrial 
complex I & III activities, NAD+ levels, and increased lactate production (Figures 2-4,6).  
In summary, our results suggest that anti-TB drugs provoke hepatotoxicity by inducing 
deficiencies in the functions of mitochondrial ETC proteins. This study also highlights toxicity 
concerns regarding multi-drug combinatorial usage, and the importance of pre-clinical in-vitro 
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testing of newly discovered anti-TB drug combinations on cellular bioenergetics, as this 
approach may provide a useful predictive index of hepatotoxic potential.  
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Table 1: Hepatotoxicity f anti-TB drugs. 
Hep G2 cells were treated with the anti-TB drugs RIF, INH, & PZA, for 4, 24, & 48 hours and 
the drug concentration producing 50 % inhibition (IC50 values) of cellular ATP production 
determined. 
 
Figure Legends: 
Figure 1: Hepatotoxicity of anti-TB drugs. 
HepG2 cells were treated with the anti-TB drugs RIF, INH, & PZA, and cellular ATP levels 
measured after 4 hours (red circles), 24 hours (orange squares), & 48 hours (green triangles).  
Graphs depict mean values relative to vehicle control values of 100 %, with significant changes 
from controls marked with asterisks.  For significance: *** = p < 0.001,** = p < 0.01, and * = p 
< 0.05. 
Figure 2: Effect of anti-TB drugs on HepG2 cell mitochondrial membrane potential. 
HepG2 cells were incubated with anti-TB drugs at the concentrations listed for 24 hours and then 
the mitochondrial membrane potential measured using a mitotracker green assay.  Histograms 
are displayed relative to vehicle control values of 100 %, with significant changes from controls 
marked with asterisks.  For significance: ** = p < 0.01, and * = p < 0.05. 
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Figure 3: Effect of anti-TB drugs on HepG2 cell mitochondrial Complex I and Complex III 
activities. 
HepG2 cells were incubated with anti-TB drugs at the concentrations listed for 24 hours and then 
mitochondrial complex I and complex III activities were measured.  Histograms are displayed 
relative to vehicle control values of 100 %, with significant changes from controls marked with 
asterisks.  For significance: *** = p < 0.001, and * = p < 0.05. 
Figure 4: Effect of anti-TB drugs on HepG2 cell NAD+ levels. 
HepG2 cells were incubated with anti-TB drugs at the concentrations listed for 24 hours and then 
NAD+ levels measured. Histograms are displayed relative to vehicle control values of 100 %, 
with significant changes from controls marked with asterisks.  For significance: * = p < 0.05. 
Figure 5: Effect of combinations of anti-TB drugs on HepG2 cell mitochondrial Complex I 
activity. 
HepG2 cells were pre-incubated with RIF, INH, & PZA at 30 µM, 3 mM, & 3 mM, respectively 
for 48 hours.  Cells were subsequently treated with anti-TB drugs at the concentrations detailed 
for 24 hours and then mitochondrial complex I activity measured.  Significant changes from 
dual-drug vs single drug incubations are marked with asterisks.  For significance: ** = p < 0.01, 
and * = p < 0.05. 
Figure 6: Effect of anti-TB drugs on HepG2 cellular lactate production. 
HepG2 cells were incubated with anti-TB drugs at the concentrations listed for 24 hours and then 
the level of lactate produced was measured.  Histograms are displayed relative to vehicle control 
values of 100 %, with significant changes from controls marked with asterisks.  For significance: 
*** = p < 0.001, and * = p < 0.05. 
Figure 7: Effect of anti-TB drugs on HepG2 cell ultrastructure. 
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HepG2 cells were incubated with (A) Vehicle control, (B) RIF at 0.5 mM, (C) INH at 70 mM, 
(D) PZA at 84 mM for 24 hours and then cellular ultrastructure assessed by TEM.  Electron 
micrographs depict at least one nucleus.  A control rod-like mitochondrion is marked with an 
asterisk (panel A), smaller, spherical mitochondrion marked with an arrowhead (panels B,C,D), 
and presumed mitophagolysosomes marked with a long arrow (panel B).  White bar denotes 
5000 nm. 
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Figure 1: Hepatotoxicity of anti-TB drugs.  
HepG2 cells were treated with the anti-TB drugs RIF, INH, & PZA, and cellular ATP levels measured after 4 
hours (red circles), 24 hours (orange squares), & 48 hours (green triangles).  Graphs depict mean values 
relative to vehicle control values of 100 %, with significant changes from controls marked with 
asterisks.  For significance: *** = p < 0.001,** = p < 0.01, and * = p < 0.05.  
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Figure 2: Effect of anti-TB drugs on HepG2 cell mitochondrial membrane potential.  
HepG2 cells were incubated with anti-TB drugs at the concentrations listed for 24 hours and then the 
mitochondrial membrane potential measured using a mitotracker green assay.  Histograms are displayed 
relative to vehicle control values of 100 %, with significant changes from controls marked with 
asterisks.  For significance: ** = p < 0.01, and * = p < 0.05.  
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Figure 3: Effect of anti-TB drugs on HepG2 cell mitochondrial Complex I and Complex III activities.  
HepG2 cells were incubated with anti-TB drugs at the concentrations listed for 24 hours and then 
mitochondrial complex I and complex III activities were measured.  Histograms are displayed relative to 
vehicle control values of 100 %, with significant changes from controls marked with asterisks.  For 
significance: *** = p < 0.001, and * = p < 0.05.  
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Figure 4: Effect of anti-TB drugs on HepG2 cell NAD+ levels.  
HepG2 cells were incubated with anti-TB drugs at the concentrations listed for 24 hours and then NAD+ 
levels measured. Histograms are displayed relative to vehicle control values of 100 %, with significant 
changes from controls marked with asterisks.  For significance: * = p < 0.05.  
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Figure 5: Effect of combinations of anti-TB drugs on HepG2 cell mitochondrial Complex I activity.  
HepG2 cells were pre-incubated with RIF, INH, & PZA at 30 µM, 3 mM, & 3 mM, respectively for 48 
hours.  Cells were subsequently treated with anti-TB drugs at the concentrations detailed for 24 hours and 
then mitochondrial complex I activity measured.  Significant changes from dual-drug vs single drug 
incubations are marked with asterisks.  For significance: ** = p < 0.01, and * = p < 0.05.  
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Figure 6: Effect of anti-TB drugs on HepG2 cellular lactate production.  
HepG2 cells were incubated with anti-TB drugs at the concentrations listed for 24 hours and then the level of 
lactate produced was measured.  Histograms are displayed relative to vehicle control values of 100 %, with 
significant changes from controls marked with asterisks.  For significance: *** = p < 0.001, and * = p < 
0.05.  
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Figure 7: Effect of anti-TB drugs on HepG2 cell ultrastructure.  
HepG2 cells were incubated with (A) Vehicle control, (B) RIF at 0.5 mM, (C) INH at 70 mM, (D) PZA at 84 
mM for 24 hours and then cellular ultrastructure assessed by TEM.  Electron micrographs depict at least one 
nucleus.  A control rod-like mitochondrion is marked with an asterisk (panel A), smaller, spherical 
mitochondrion marked with an arrowhead (panels B,C,D), and presumed mitophagolysosomes marked with 
a long arrow (panel B).  White bar denotes 5000 nm.  
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Table 1: Hepatotoxicity of anti-TB drugs. 
Drug Chemical structure 
IC50 concentration (mM) 
4 hr 24 hr 48 hr 
Rifampicin 
(RIF) 
 
0.8 0.5 0.5 
Isoniazid 
(INH) 
 
94 70 57 
Pyrazinamide 
(PZA) 
 
135 84 57 
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